Category: Moms

Creatine for reducing mental fatigue

Creatine for reducing mental fatigue

Creatine nental reduces skeletal muscle degeneration and enhances mitochondrial function Creqtine mdx mice. Konstantinos Prokopidis and Panagiotis Giannos contributed Continuous glucose monitoring for diabetes Creatine for reducing mental fatigue this work. Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial. Animal models have provided promising evidence that creatine supplementation prior to inducing TBIs may be neuroprotective [ 56 ]. Creatine as a booster for human brain function. McMorris TMielcarz GHarris RCet al.

Creatine for reducing mental fatigue -

Potential for use of creatine supplementation following mild traumatic brain injury. Vedung F, Fahlström M, Wall A, Antoni G, Lubberink M, Johansson J, et al. Chronic cerebral blood flow alterations in traumatic brain injury and sports-related concussions.

Brain Inj. Sullivan P, Geiger J, Mattson M, Scheff S. Dietary supplement creatine protects against traumatic brain injury.

Ann Neurol. Scheff SW, Dhillon HS. Creatine-enhanced diet alters levels of lactate and free fatty acids after experimental brain injury. Neurochem Res. Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases.

Acta Pharmacol Sin. Masse I, Moquin L, Bouchard C, Gratton A, De Beaumont L. Efficacy of prophylactic versus therapeutic administration of the NMDA receptor antagonist MK on the acute neurochemical response to a concussion in a rat model combining force and rotation.

J Neurosurg. Genius J, Geiger J, Bender A, Möller HJ, Klopstock T, Rujescu D. Creatine protects against excitoxicity in an in vitro model of neurodegeneration.

PLoS ONE. Saraiva ALL, Ferreira APO, Silva LFA, Hoffmann MS, Dutra FD, Furian AF, et al. Creatine reduces oxidative stress markers but does not protect against seizure susceptibility after severe traumatic brain injury.

Brain Res Bull. Sakellaris G, Kotsiou M, Tamiolaki M, Kalostos G, Tsapaki E, Spanaki M, et al. Prevention of complications related to traumatic brain injury in children and adolescents with creatine administration: an open label randomized pilot study.

J Trauma. Sakellaris G, Nasis G, Kotsiou M, Tamiolaki M, Charissis G, Evangeliou A. Prevention of traumatic headache, dizziness and fatigue with creatine administration: a pilot study.

Acta Paediatr. Chaychi S, Valera E, Tartaglia MC. Int Rev Neurobiol. Barnham KJ, Masters CL, Bush AI.

Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, et al. Creatine and multiple sclerosis. Nutr Neurosci. Soria Lopez JA, González HM, Léger GC. Handb Clin Neurol.

Rijpma A, van der Graaf M, Meulenbroek O, Olde Rikkert MGM, Heerschap A. NeuroImage Clin. Pettegrew JW, Panchalingam K, Klunk WE, McClure RJ, Muenz LR. Neurobiol Aging. Aksenov MY, Aksenova MV, Payne RM, Smith CD, Markesbery WR, Carney JM.

Exp Neurol. Laakso MP, Hiltunen Y, Könönen M, Kivipelto M, Koivisto A, Hallikainen M, et al. Decreased brain creatine levels in elderly apolipoprotein E ε4 carriers.

J Neural Transm. Brewer GJ, Wallimann TW. Protective effect of the energy precursor creatine against toxicity of glutamate and β-amyloid in rat hippocampal neurons. J Neurochem. Perez Ortiz JM, Swerdlow RH. Br J Pharmacol.

Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. Alimohammadi-Kamalabadi M, Eshraghian M, Zarindast M, Aliaghaei A, Pishva H.

Iran J Basic Med Sci. Ray Dorsey E, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, et al. Lancet Neurol.

Sveinbjornsdottir S. Sagna A, Gallo JJ, Pontone GM. Parkinsonism Relat Disord. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity.

Klein AM, Ferrante RJ. The neuroprotective role of creatine. Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.

Li Z, Wang P, Yu Z, Cong Y, Sun H, Zhang J, et al. Eur Neurol. Ravina B, Kieburtz K, Tilley B, Shannon K, Tanner C, Frederick Wooten G, et al. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.

Kieburtz K, Tilley B, Ravina B, Galpern WR, Shannon K, Tanner C, et al. A pilot clinical trial of creatine and minocycline in early Parkinson disease: month results. Clin Neuropharmacol. Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Goldenberg MM. Multiple sclerosis review. Pharm Ther. Dalgas U, Langeskov-Christensen M, Stenager E, Riemenschneider M, Hvid LG. Exercise as medicine in multiple sclerosis: time for a paradigm shift: preventive, symptomatic, and disease-modifying aspects and perspectives.

Curr Neurol Neurosci Rep. Taul-Madsen L, Connolly L, Dennett R, Freeman J, Dalgas U, Hvid LG. Is aerobic or resistance training the most effective exercise modality for improving lower extremity physical function and perceived fatigue in people with multiple sclerosis?

A systematic review and meta-analysis. Arch Phys Med Rehabil. Beer M, Sandstede J, Weilbach F, Spindler M, Buchner S, Krug A, et al. Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study. Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, et al.

Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Lynch J, Peeling J, Auty A, Sutherland G. Nuclear magnetic resonance study of cerebrospinal fluid from patients with multiple sclerosis.

Can J Neurol Sci. Lambert CP, Archer RL, Carrithers JA, Fink WJ, Evans WJ, Trappe TA. Influence of creatine monohydrate ingestion on muscle metabolites and intense exercise capacity in individuals with multiple sclerosis. Malin SK, Cotugna N, Fang CS. Effect of creatine supplementation on muscle capacity in individuals with multiple sclerosis.

J Diet Suppl. Zucchi E, Bonetto V, Sorarù G, Martinelli I, Parchi P, Liguori R, et al. Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers.

Mol Neurodegener. Gittings LM, Sattler R. Recent advances in understanding amyotrophic lateral sclerosis and emerging therapies.

Fac Rev. Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine.

Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Wyss M, Schulze A. Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease?

Beal MF. Neuroprotective effects of creatine. Klopstock T, Elstner M, Bender A. Creatine in mouse models of neurodegeneration and aging. Hervias I, Beal MF, Manfredi G. Mitochondrial dysfunction and amyotrophic lateral sclerosis.

Muscle Nerve. Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, et al.

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. Andreassen OA, Jenkins BG, Dedeoglu A, Ferrante KL, Bogdanov MB, Kaddurah-Daouk R, et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation.

Derave W, Van Den Bosch L, Lemmens G, Eijnde BO, Robberecht W, Hespel P. Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment.

Neurobiol Dis. Mazzini L, Balzarini C, Colombo R, Mora G, Pastore I, De Ambrogio R, et al. Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results.

J Neurol Sci. Groeneveld GJ, Veldink JH, Van der Tweel I, Kalmijn S, Beijer C, De Visser M, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, et al.

Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al.

A clinical trial of creatine in ALS. Drory VE, Gross D. No effect of creatine on respiratory distress in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord.

Tarnopolsky M, Parise G. Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease.

Balestrino M, Adriano E. Beyond sports: efficacy and safety of creatine supplementation in pathological or paraphysiological conditions of brain and muscle.

Med Res Rev. Fitch CD, Moody LG. Creatine metabolism in skeletal muscle. An intracellular abnormality of creatine trapping in dystrophic muscle. Proc Soc Exp Biol Med. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of patients. Acta Myol.

Passaquin AC, Renard M, Kay L, Challet C, Mokhtarian A, Wallimann T, et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice.

Neuromuscul Disord. Louis M, Lebacq J, Poortmans JR, Belpaire-Dethiou M-C, Devogelaer J-P, Van HP, et al. Beneficial effects of creatine supplementation in dystrophic patients. Ogborn DI, Smith KJ, Crane JD, Safdar A, Hettinga BP, Tupler R, et al.

Effects of creatine and exercise on skeletal muscle of FRG1-transgenic mice. Tarnopolsky MA, Mahoney DJ, Vajsar J, Rodriguez C, Doherty TJ, Roy BD, et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Escolar DM, Buyse G, Henricson E, Leshner R, Florence J, Mayhew J, et al.

CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Davidson ZE, Hughes I, Ryan MM, Kornberg AJ, Cairns AG, Jones K, et al. Effect of a multicomponent nutritional supplement on functional outcomes for Duchenne muscular dystrophy: a randomized controlled trial.

Clin Nutr. Tarnopolsky M, Mahoney D, Thompson T, Naylor H, Doherty TJ. Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1.

Walter MC, Reilich P, Lochmüller H, Kohnen R, Schlotter B, Hautmann H, et al. Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study. J Neurol. Schneider-Gold C, Beck M, Wessig C, George A, Kele H, Reiners K, et al.

Proximal myotonic myopathy. Tarnopolsky M. Clinical use of creatine in neuromuscular and neurometabolic disorders. Kley R, Tarnopolsky M, Vorgerd M. Creatine for treating muscle disorders. Cochrane Database Syst Rev. McCorquodale D, Pucillo EM, Johnson NE.

Management of Charcot—Marie—Tooth disease: improving long-term care with a multidisciplinary approach. J Multidiscip Healthc. Doherty TJ, Lougheed K, Markez J, Tarnopolsky MA. Creatine monohydrate does not increase strength in patients with hereditary neuropathy. Chetlin RD, Gutmann L, Tarnopolsky MA, Ullrich IH, Yeater RA.

Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease. Smith CA, Chetlin RD, Gutmann L, Yeater RA, Alway SE. Effects of exercise and creatine on myosin heavy chain isoform composition in patients with Charcot—Marie—Tooth disease.

World Health Organization. Wiles NJ, Thomas L, Turner N, Garfield K, Kounali D, Campbell J, et al. Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial.

Lancet Psychiatry. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Jung WY, Jang SH, Kim SG, Jae YM, Kong BG, Kim HC, et al.

Times to discontinue antidepressants over 6 months in patients with major depressive disorder. Psychiatry Investig.

Cartwright C, Gibson K, Read J, Cowan O, Dehar T. Long-term antidepressant use: patient perspectives of benefits and adverse effects. Patient Prefer Adherence. Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence.

Mol Psychiatry. Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY, et al. Altered serotonin 1A binding in major depression: a [carbonyl-C]WAY positron emission tomography study. Biol Psychiatry. Howes OD, Williams M, Ibrahim K, Leung G, Egerton A, McGuire PK, et al.

Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study.

Abdallah CG, Averill CL, Salas R, Averill LA, Baldwin PR, Krystal JH, et al. Prefrontal connectivity and glutamate transmission: relevance to depression pathophysiology and ketamine treatment.

Biol Psychiatry Cogn Neurosci Neuroimaging. Persson J, Wall A, Weis J, Gingnell M, Antoni G, Lubberink M, et al. Inhibitory and excitatory neurotransmitter systems in depressed and healthy: a positron emission tomography and magnetic resonance spectroscopy study. Psychiatry Res Neuroimaging.

Kumar A, Thomas A, Lavretsky H, Yue K, Huda A, Curran J, et al. Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy.

Am J Psychiatry. Li BSY, Wang H, Gonen O. Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magn Reson Imaging. Chang L, Mehringer CM, Ernst T, Melchor R, Myers H, Forney D, et al.

Neurochemical alterations in asymptomatic abstinent cocaine users: a proton magnetic resonance spectroscopy study. Faulkner P, Lucini Paioni S, Kozhuharova P, Orlov N, Lythgoe DJ, Daniju Y, et al.

Daily and intermittent smoking are associated with low prefrontal volume and low concentrations of prefrontal glutamate, creatine, myo-inositol, and N -acetylaspartate. Addict Biol. Prescot AP, Locatelli AE, Renshaw PF, Yurgelun-Todd DA. Neurochemical alterations in adolescent chronic marijuana smokers: a proton MRS study.

Allah Yar R, Akbar A, Iqbal F. Brain Res. Öngür D, Prescot AP, Jensen JE, Cohen BM, Renshaw PF. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res. Auer DP, Pütz B, Kraft E, Lipinski B, Schill J, Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study.

Biol Psychiatr. Increased medial thalamic creatine-phosphocreatine found by proton magnetic resonance spectroscopy in children with obsessive-compulsive disorder versus major depression and healthy controls. J Child Neurol. Faulkner P, Paioni SL, Kozhuharova P, Orlov N, Lythgoe DJ, Daniju Y, et al.

Relationship between depression, prefrontal creatine and grey matter volume. J Psychopharmacol. Yue Q, Liu M, Nie X, Wu Q, Li J, Zhang W, et al. Quantitative 3. Lyoo IK, Yoon S, Kim TS, Hwang J, Kim JE, Won W, et al. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.

Nemets B, Levine J. Int Clin Psychopharmacol. Braissant O. Creatine and guanidinoacetate transport at blood-brain and blood-cerebrospinal fluid barriers. van de Kamp JM, Pouwels PJW, Aarsen FK, ten Hoopen LW, Knol DL, de Klerk JB, et al.

Long-term follow-up and treatment in nine boys with X-linked creatine transporter defect. Pazini FL, Cunha MP, Rosa JM, Colla ARS, Lieberknecht V, Oliveira Á, et al. Mol Neurobiol. Assis LC, Rezin GT, Comim CM, Valvassori SS, Jeremias IC, Zugno AI, et al.

Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats. Rev Bras Psiquiatr. Kious BM, Kondo DG, Renshaw PF. Creatine for the treatment of depression.

Mirowsky J, Ross CE. Age and depression. J Health Soc Behav. Lind A, Boraxbekk CJ, Petersen ET, Paulson OB, Siebner HR, Marsman A. Regional myo-inositol, creatine, and choline levels are higher at older age and scale negatively with visuospatial working memory: a cross-sectional proton MR spectroscopy study at 7 Tesla on normal cognitive ageing.

Brown MS, Singel D, Hepburn S, Rojas DC. Increased glutamate concentration in the auditory cortex of persons with autism and first-degree relatives: a 1 H-MRS study.

Autism Res. Nagae-Poetscher LM, Bonekamp D, Barker PB, Brant LJ, Kaufmann WE, Horská A. Asymmetry and gender effect in functionally lateralized cortical regions: a proton MRS imaging study.

J Magn Reson Imaging. Pouwels PJW, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med. Tayoshi S, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, Iga J, et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy 1H-MRS.

Schizophr Res. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. Download references. This supplement is supported by the Gatorade Sports Science Institute GSSI.

The supplement was guest edited by Dr. Lawrence L. Spriet, who convened a virtual meeting of the GSSI Expert Panel in October and received honoraria from the GSSI, a division of PepsiCo, Inc.

Spriet received no honoraria for guest editing this supplement. Spriet suggested peer reviewers for each paper, which were sent to the Sports Medicine Editor-in-Chief for approval, prior to any reviewers being approached. Spriet provided comments on each paper and made an editorial decision based on comments from the peer reviewers and the Editor-in-Chief.

Where decisions were uncertain, Dr. Spriet consulted with the Editor-in-Chief. The views expressed in this manuscript are those of the authors and do not necessarily reflect the position or policy of PepsiCo, Inc. Department of Physical Education Studies, Brandon University, Brandon, MB, Canada.

Department of Nutrition and Public Health, University of Agder, Kristiansand, Norway. Department of Musculoskeletal Biology, University of Liverpool, Liverpool, UK.

School of Kinesiology and Rehabilitation Sciences, University of Central Florida, Orlando, FL, USA. Department of Exercise Science, Syracuse University, New York, NY, USA.

Department of Psychology, University of Roehampton, London, UK. You can also search for this author in PubMed Google Scholar. Correspondence to Darren G. This article is based on a presentation by Darren G.

Candow to the GSSI Expert Panel in October Funding for participation in that meeting together with an honorarium for preparation of this article were provided by the GSSI. No other sources of funding were used to assist in the preparation of this article.

DGC has conducted industry-sponsored research involving creatine supplementation and received creatine donations for scientific studies and travel support for presentations involving creatine supplementation at scientific conferences.

But creatine is likely also useful in brain fog and other cognitive symptoms. Interestingly, there seems to be a beneficial effect on aging muscle even if someone is not resistance training although there are studies going both ways.

While my patient population is not largely athletic performance focused, there is a lot of utility of creatine in chronic illness as well.

This model of inflammation is quite useful in many conditions that I treat, including chronic infections, postinfectious conditions with immune system abnormalities persisting, and toxicities.

Going back to the performance world, creatine may benefit not only weight training but also aerobic performance. A study in marathon runners found certain inflammatory markers being reduced including the cytokine tumor necrosis factor alpha as well as prostaglandin E2.

There was also a reduction in creatine kinase in the blood, which is a marker for muscle cell breakdown. There is some theoretical data that there may be anti-inflammatory effects in aerobic exercise but not resistance exercise.

Other conditions that have low-grade inflammation showed some benefit as well. The study titled Use of creatine in the elderly and evidence for effects on cognitive function in young and old found benefit in cognition when deficits were produced either with sleep deprivation, or if there were deficits due to aging.

There was a double-blind trial that used 8 g of creatine for five days showing reduction in mental fatigue with mathematical processing. Imaging done in the studies suggested that there was better oxygen uptake and utilization in the brain. It found that the effect was greater when external stressors were present.

A study in depression also found benefit with creatine supplementation that was both dose and absorption dependent. Part of the mechanism was thought to be related to creatine supporting BDNF brain derived neurotrophic factor , as compounds that inhibited this block be effective creatine.

Some of the improvements in cognition with the use of creatine might also be attributed to improvements in mitochondrial function. Mitochondrial dysfunction is common to many chronic illnesses, and accordingly not unique.

Key points Creatine is most commonly known as a sports supplement to enhance physical performance. New research indicates that creatine is also important to brain function, affecting mood and cognition.

Early trials suggest creatine supplementation can improve stress resilience, depression, and brain functions such as memory. References 1. About the Author. More from Thomas Rutledge Ph. More from Psychology Today.

Back Psychology Today. Back Find a Therapist. Get Help Find a Therapist Find a Treatment Centre Find Online Therapy Members Login Sign Up Canada Calgary, AB Edmonton, AB Hamilton, ON Montréal, QC Ottawa, ON Toronto, ON Vancouver, BC Winnipeg, MB Mississauga, ON London, ON Guelph, ON Oakville, ON.

Back Get Help. Mental Health. Personal Growth. Family Life. View Help Index. Do I Need Help? Talk to Someone. Back Magazine. January Overcome burnout, your burdens, and that endless to-do list.

Back Today. Essential Reads.

Redkcing The reduclng of the brain in Creatjne was recently confirmed by the negative effect of mental fatigue Reducibg on sport-specific psychomotor Joint health endurance. Creatine supplementation improves Creatinee but can also improve cognitive functioning. To explore the role of creatine in combating MF, we evaluated whether creatine supplementation counteracts the MF-associated impairment in sport-specific psychomotor skills. In both conditions, a 7-min sport-specific visuomotor task, a dynamic handgrip strength endurance task, and a 3-min Flanker task was performed before and after the mentally fatiguing task. Physiological and perceptual responses were measured throughout the protocol. Creatine fafigue Creatine for reducing mental fatigue well-known supplement that is used in the bodybuilding world. It is normally used Hyperglycemia management strategies improve short-term energy generation when lifting weights. Fxtigue sources include red meat, seafood, and poultry. The amino acid sources are arginine, glycine, and methionine. Dietary shortfalls can be made up by production in the kidney and liver. Many supplement it before workouts. But creatine is likely also useful in brain fog and other cognitive symptoms. Creatine for reducing mental fatigue

Author: Tygotaxe

1 thoughts on “Creatine for reducing mental fatigue

Leave a comment

Yours email will be published. Important fields a marked *

Design by ThemesDNA.com